Primary sclerosing cholangitis

Marathon Runners Take to the Windy City to Raise Awareness of Liver Disease

Retrieved on: 
Wednesday, October 4, 2023
Chicago Marathon, Travel, University, ALF, University of Michigan, Life, Liver disease, Grant Park, American Liver Foundation, Primary sclerosing cholangitis, Research, Liver cancer, MHS, Running, MD, Patient, Physician, Non-alcoholic fatty liver disease, Gambat Liver Transplant Center, Bank, Team, Dietary supplement

FAIRFIELD, N.J., Oct. 4, 2023 /PRNewswire/ -- The American Liver Foundation (ALF) is proud to once again be a member of the Bank of America Chicago Marathon Official Charity Program for the 2023 race, which takes place on Sunday, October 8, 2023, in iconic Grant Park.

Key Points: 
  • "There are nearly 100 million people in the U.S. affected by liver disease, and most aren't aware they even have it.
  • That's why we are so honored that these runners have chosen to join us to help raise awareness and funds to combat liver disease."
  • The American Liver Foundation's Bank of America Chicago Marathon team has already met their fundraising goal and has since increased it.
  • The American Liver Foundation team is made up of runners with varying levels of experience from novice to advanced, most of whom have a connection to liver disease.

Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference

Retrieved on: 
Thursday, September 28, 2023
CCL24, Liver, Fibrosis, Optimism, Therapy, Cirrhosis, NASH, The Yale Club of New York City, CMMB, Inflammation, Biomarker, Doctor of Philosophy, ELF, TEL, Patient, Fatty liver disease, FDA, III, Conference, Primary sclerosing cholangitis, Pharmaceutical industry, Vaccine, Medical imaging, PSC

TEL AVIV, Israel, Sept. 28, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced that Chemomab co-founder, Chief Executive Officer and Chief Scientific Officer Adi Mor, PhD, will discuss the CM-101 clinical program in primary sclerosing cholangitis (PSC) at the 2023 Roth MKM Healthcare Opportunities Conference on October 12, 2023. The conference is being held at the Yale Club in New York City. Dr. Mor will give a live presentation at 12:00 noon ET and company executives will participate in one-on-one meetings with investors.

Key Points: 
  • TEL AVIV, Israel, Sept. 28, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced that Chemomab co-founder, Chief Executive Officer and Chief Scientific Officer Adi Mor, PhD, will discuss the CM-101 clinical program in primary sclerosing cholangitis (PSC) at the 2023 Roth MKM Healthcare Opportunities Conference on October 12, 2023.
  • Unlike the other drugs in clinical development for PSC, CM-101 has a unique dual mechanism of action that simultaneously blocks fibrosis and inflammation.
  • Earlier this year, Chemomab reported positive results from a Phase 2a liver fibrosis trial in patients with nonalcoholic steatohepatitis (NASH).
  • To register for the 2023 Roth-MKM Healthcare Opportunities Conference, click here , or contact a Roth MKM sales representative.

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Retrieved on: 
Tuesday, September 26, 2023
Tissue, University, Cirrhosis, Ursodeoxycholic acid, TGF, Week, IBD, Liver disease, Telephone, ALP, Pharmacokinetics, Hyaluronic acid, Inflammation, ELF, Interest, EMA, Alkaline phosphatase, Inflammatory bowel disease, Plasma, Fibrosis, MRI, Conference call, SAE, Magnetic resonance imaging, HIV disease progression rates, Patient, SAN, Itch, UDCA, Webcast, ALT, Liver, FDA, IPF, PSC, AST, Therapy, Liver failure, Primary sclerosing cholangitis, Safety, III, Disease, Conference, Medical imaging, Pharmaceutical industry, Medicine

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced positive data from INTEGRIS-PSC, a Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe liver fibrosis. The trial met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period and its plasma concentrations increased with dose. The trial’s exploratory efficacy endpoints assessed changes in the liver fibrosis markers, Enhanced Liver Fibrosis (ELF) score and PRO-C3 levels, as well as liver biochemistry and magnetic resonance imaging (MRI) of the liver. Results at the initial three doses tested showed bexotegrast reduced both ELF scores and PRO-C3 levels at Week 12 at all doses relative to placebo with statistically significant differences at the 160 mg dose relative to placebo at Week 12. Patients also showed stabilization of liver chemistry, including a dose-dependent trend in reduction of alkaline phosphatase (ALP) levels, relative to placebo at Week 12. In addition, preliminary MRI imaging results suggest improved hepatocyte function and bile flow with bexotegrast 160 mg. Twelve-week interim data from the high-dose 320 mg cohort is expected in the first quarter of 2024.

Key Points: 
  • ET
    SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced positive data from INTEGRIS-PSC, a Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe liver fibrosis.
  • The trial’s exploratory efficacy endpoints assessed changes in the liver fibrosis markers, Enhanced Liver Fibrosis (ELF) score and PRO-C3 levels, as well as liver biochemistry and magnetic resonance imaging (MRI) of the liver.
  • We believe INTEGRIS-PSC to be the first randomized clinical trial to use an enrichment strategy to enroll patients with suspected moderate to severe liver fibrosis based on liver stiffness measure, ELF score or historical liver biopsy.
  • The exploratory endpoints of the INTEGRIS-PSC trial include changes in liver fibrosis markers, ELF and PRO-C3, liver biochemistry and MRI imaging.

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023
Duchenne muscular dystrophy, Therapy, Senior, TGF, Doctor of Philosophy, Serum, ALP, Pharmacokinetics, FVC, Biomarker, Duchenne, QLF, ELF, Alkaline phosphatase, Fibrosis, Vital capacity, DMD, Novartis, Patient, Investment, SAN, Integrin, IPF, PSC, IND, Tumor microenvironment, Idiopathic pulmonary fibrosis, Primary sclerosing cholangitis, Cirrhosis, Safety, Pharmaceutical industry, Medical imaging, Research

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second quarter 2023 financial results.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second quarter 2023 financial results.
  • INTEGRIS-IPF Phase 2a 24-week 320 mg clinical data showed bexotegrast was well tolerated and demonstrated durable improvements in exploratory efficacy endpoints.
  • INTEGRIS-PSC Phase 2a 12-week interim data expected in the third quarter of 2023.
  • Interim 12-week data from approximately 84 patients in the 40, 80 and 160 mg cohorts is expected in the third quarter of 2023.

Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 3, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Exercise, ALGS, Partnership, CTX, Spiroplasma mirum, Event, Hepatology, Travers Smith, PBC, VISTAS, Prescription Drug User Fee Act, Primary sclerosing cholangitis, Biliary atresia, CAMEO, Sale, Medication, Alagille syndrome, Cholic acid, Primary biliary cholangitis, Shanda, Acquisition, Patient, Investment, Itch, Bilirubin, PDUFA, Webcast, Therapy, PSC, Cholestatic pruritus, Volixibat, Pharmaceutical industry, Security (finance), Video game

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for second quarter 2023 and provided a business update.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for second quarter 2023 and provided a business update.
  • Mirum to pay $210 million upfront and up to $235 million in potential tiered annual net sales-based milestones.
  • Second quarter 2023 global net sales grew 86% as compared to second quarter 2022, on track for 50% US net product sales growth in 2023 as compared to 2022.
  • Total operating expenses were $61.8 million for the quarter ended June 30, 2023 in comparison to $48.9 million for the quarter ended June 30, 2022.

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

Retrieved on: 
Friday, June 23, 2023
EASL, Therapy, TGF, DSMB, PBC, Pharmacokinetics, PET, Data monitoring committee, Fibrosis, Primary biliary cholangitis, Patient, Injury, SAN, Integrin, European Association for the Study of the Liver, PSC, Idiopathic pulmonary fibrosis, Primary sclerosing cholangitis, Safety, Pharmaceutical industry, Liver

“PSC is a rare chronic autoimmune disease with no effective therapy, representing a large unmet need for new treatments.

Key Points: 
  • “PSC is a rare chronic autoimmune disease with no effective therapy, representing a large unmet need for new treatments.
  • Our presentations this week discuss the early non-clinical work that support our ongoing Phase 2a clinical program.
  • We look forward to sharing interim data from this trial in the third quarter,” said Éric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics.
  • The effects of bexotegrast on individual cell populations were evaluated in fibrotic PSC and primary biliary cholangitis (PBC) precision-cut liver slices.

Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis

Retrieved on: 
Friday, June 2, 2023
CCL24, University, Therapy, Serum, European Alliance of Associations for Rheumatology, CMMB, ILD, Prognosis, Primary sclerosing cholangitis, Scleroderma, Doctor of Philosophy, TEL, Incidence, Congress, Patient, European, DSM-IV codes, Risk, Poster, R, EULAR, European Alliance, Systemic scleroderma, Disease, Pharmaceutical industry, Rheumatology

MILAN and TEL AVIV, Israel, June 2, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced a poster presentation at the 2023 European Congress of Rheumatology, hosted by the European Alliance of Association for Rheumatology (EULAR) and held in Milan, Italy May 31–June 3, 2023.

Key Points: 
  • The poster, "CCL24 serum concentration predicts both vascular and fibrotic complications in systemic sclerosis," was presented today by Professor Enrico De Lorenzis of the Leeds Institute of Rheumatic and Musculoskeletal Diseases at the University of Leeds in the UK.
  • The study was conducted by Professor De Lorenzis and his colleagues who enrolled systemic sclerosis (SSc) patients from an observational cohort and compared them with age- and gender-matched controls.
  • 1 - CCL24 serum concentration predicts both vascular and fibrotic complications in systemic sclerosis, Enrico De Lorenzis, Adi Mor, Rebecca Ross, Stefano Di Donato, Revital Aricha, Hilit Levi, Ilan Vaknin, Francesco Del Galdo
    A copy of the poster will be available at the R&D portion of Chemomab's website.
  • For more information on the EULAR Congress, visit https://congress.eular.org/

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

Retrieved on: 
Thursday, June 1, 2023
Partnership, Primary sclerosing cholangitis, Liver disease, Clinical trial, Health equity, TEL, Virginia Commonwealth University, Liver, Research, PSC, Danny Galm, Pharmaceutical industry, Medical device, Cryptocurrency, Oncae

Financial Summary – First Quarter 2023 vs. First Quarter 2022:

Key Points: 
  • Financial Summary – First Quarter 2023 vs. First Quarter 2022:
    Cash and cash equivalents, short term deposit, restricted cash and marketable debt securities totaled $12.2 million as of March 31, 2023, compared to $13.8 million at December 31, 2022.
  • Research and development expenses amounted to approximately $1.1 million for the three months ended March 31, 2023, compared to approximately $4.8 million for the three months ended March 31, 2022.
  • General and administrative expenses amounted to approximately $0.9 million for the three months ended March 31, 2023, compared to approximately $1.3 million for the three months ended March 31, 2022.
  • Financial income, net amounted to approximately $0.2 million for the three months ended March 31, 2023, compared to financial expense of $0.05 million for the three months ended March 31, 2022.

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

Retrieved on: 
Wednesday, May 24, 2023
CCL24, EASL, Therapy, NASH, Liver, CMMB, Inflammation, Scleroderma, European Congress of Radiology, Doctor of Philosophy, Fibrosis, TEL, Congress, Patient, European Association for the Study of the Liver, EULAR, PSC, Systemic scleroderma, Primary sclerosing cholangitis, Pharmaceutical industry, Rheumatology

TEL AVIV, Israel, May 24, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced upcoming CM-101 data presentations at major European scientific conferences in June 2023, including EULAR23, the European Congress of Rheumatology, and EASL 2023, the Annual Congress of the European Association for the Study of the Liver.

Key Points: 
  • TEL AVIV, Israel, May 24, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced upcoming CM-101 data presentations at major European scientific conferences in June 2023, including EULAR23, the European Congress of Rheumatology, and EASL 2023, the Annual Congress of the European Association for the Study of the Liver.
  • Further details of the presented data will be forthcoming.
  • "Our poster presentations at EULAR and EASL highlight the novelty and potential of our unique approach to fibro-inflammatory diseases," said Dale Pfost, PhD, CEO of Chemomab.
  • EULAR23 – European Congress of Rheumatology – Milan, Italy, May 31-June 3, 2023

Hepatology Communications Publishes Data from Mirum’s LIVMARLI in Primary Sclerosing Cholangitis

Retrieved on: 
Thursday, May 18, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, University, Spiroplasma mirum, Ascending cholangitis, Gastroenterology, Diarrhea, SBA, VISTAS, Quality of life, Research, CAMEO, Doctor of Philosophy, Abdominal pain, Medication, University of California, Davis, MD, Patient, Itch, Nausea, IBAT, PSC, Primary sclerosing cholangitis, Safety, Pharmaceutical industry

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that Hepatology Communications published data from the CAMEO study evaluating the safety, tolerability, and efficacy of LIVMARLI® (maralixibat) oral solution in patients with primary sclerosing cholangitis (PSC).

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that Hepatology Communications published data from the CAMEO study evaluating the safety, tolerability, and efficacy of LIVMARLI® (maralixibat) oral solution in patients with primary sclerosing cholangitis (PSC).
  • The open-label study (n=27) evaluated the safety and tolerability of LIVMARLI for 14 weeks in adults with PSC measuring pruritus, serum bile acid levels, and liver function.
  • In this open-label Phase 2 pilot study, pruritus scores and serum bile acid concentration decreased over the 14 weeks of treatment with LIVMARLI.
  • We are grateful to the clinicians and patients who participated in the CAMEO study and thank them for their contribution.”